Related Experiment Videos
Localized non-Hodgkin lymphoma involving the thyroid gland
C S Ha1, K M Shadle, L J Medeiros
1Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA. chulha@mdanderson.org
Cancer
|March 10, 2001
Summary
Localized non-Hodgkin lymphoma (NHL) of the thyroid has a good prognosis, particularly with combined modality therapy (CMT). Distant recurrences are the main cause of treatment failure, with the International Prognostic Index (IPI) predicting overall survival.
Area of Science:
- Oncology
- Hematology
- Thyroid Cancer Research
Background:
- Non-Hodgkin lymphoma (NHL) can involve the thyroid gland.
- Understanding the natural history and failure patterns of localized thyroid NHL is crucial.
Purpose of the Study:
- To define the natural history of localized thyroid non-Hodgkin lymphoma.
- To identify patterns of treatment failure in these patients.
Main Methods:
- Retrospective review of 51 patients with Ann Arbor Stage I or II thyroid NHL.
- Analysis of treatment modalities including surgery, radiation, chemotherapy, and combined modality therapy (CMT).
- Evaluation of prognostic factors such as International Prognostic Index (IPI), disease stage, and mediastinal involvement for overall survival (OS) and failure-free survival (FFS).
Main Results:
- Five-year OS and FFS rates were 64% and 76%, respectively.
- Combined modality therapy (CMT) showed a trend towards better FFS (91%) compared to other regimens.
- International Prognostic Index (IPI) was a significant predictor of OS (P=0.02) and marginally for FFS (P=0.08).
Conclusions:
- Localized thyroid NHL has a favorable prognosis, especially with CMT.
- Distant recurrences are the primary cause of treatment failure.
- IPI is a significant prognostic factor for OS in this patient group.